These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

77 related items for PubMed ID: 1793066

  • 21. Protective effect of SR 27417, a novel PAF antagonist, on PAF- or endotoxin-induced hypotension in the rat and the guinea-pig.
    Bernat A, Herbert JM, Salel V, Lespy L, Maffrand JP.
    J Lipid Mediat; 1992 Feb; 5(1):41-8. PubMed ID: 1391738
    [Abstract] [Full Text] [Related]

  • 22. Inhibitory effect of UK,74505, a potent and specific oral platelet activating factor (PAF) receptor antagonist, on airway and systemic responses to inhaled PAF in humans.
    O'Connor BJ, Uden S, Carty TJ, Eskra JD, Barnes PJ, Chung KF.
    Am J Respir Crit Care Med; 1994 Jul; 150(1):35-40. PubMed ID: 8025768
    [Abstract] [Full Text] [Related]

  • 23. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist. Effects on microvascular permeability, hypotension and nephrosis.
    Sakuma Y, Shirato M, Nagaoka J, Obaishi H, Tsunoda H, Katayama S, Ono H, Katayama K.
    Arzneimittelforschung; 1991 Dec; 41(12):1255-9. PubMed ID: 1815526
    [Abstract] [Full Text] [Related]

  • 24. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
    Hwang SB, Lam MH, Szalkowski DM, MacIntyre DE, Bach TJ, Luell S, Meuer R, Sahoo SP, Alberts AW, Chabala JC.
    J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114
    [Abstract] [Full Text] [Related]

  • 25. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
    Hwang SB, Lam MH, Alberts AW, Bugianesi RL, Chabala JC, Ponpipom MM.
    J Pharmacol Exp Ther; 1988 Aug; 246(2):534-41. PubMed ID: 2841449
    [Abstract] [Full Text] [Related]

  • 26. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
    Imanishi N, Murakami-Uchida M, Koike H, Natsume Y, Morooka S.
    Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
    [Abstract] [Full Text] [Related]

  • 27. Inhibition of PAF-induced systemic responses in the rat, guinea pig, dog and primate by the receptor antagonist SRI 63-441.
    Handley DA, Tomesch JC, Saunders RN.
    Thromb Haemost; 1986 Aug 20; 56(1):40-4. PubMed ID: 3775689
    [Abstract] [Full Text] [Related]

  • 28. 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives.
    Cooper K, Fray MJ, Parry MJ, Richardson K, Steele J.
    J Med Chem; 1992 Aug 21; 35(17):3115-29. PubMed ID: 1507200
    [Abstract] [Full Text] [Related]

  • 29. The isolation and characterization of kadsurenone from haifenteng (Piper futokadsura) as an orally active specific receptor antagonist of platelet-activating factor.
    Shen TY, Hwang SB, Chang MN, Doebber TW, Lam MH, Wu MS, Wang X.
    Int J Tissue React; 1985 Aug 21; 7(5):339-43. PubMed ID: 2997065
    [Abstract] [Full Text] [Related]

  • 30. Inhibitory effect of epinastine on bronchoconstriction induced by histamine, platelet activating factor and serotonin in guinea pigs and rats.
    Tasaka K, Kamei C, Nakamura S.
    Arzneimittelforschung; 1994 Mar 21; 44(3):327-9. PubMed ID: 7910745
    [Abstract] [Full Text] [Related]

  • 31. MEN16132, a novel potent and selective nonpeptide kinin B2 receptor antagonist: in vivo activity on bradykinin-induced bronchoconstriction and nasal mucosa microvascular leakage in anesthetized guinea pigs.
    Valenti C, Cialdai C, Giuliani S, Lecci A, Tramontana M, Meini S, Quartara L, Maggi CA.
    J Pharmacol Exp Ther; 2005 Nov 21; 315(2):616-23. PubMed ID: 16027229
    [Abstract] [Full Text] [Related]

  • 32. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.
    Terashita Z, Imura Y, Takatani M, Tsushima S, Nishikawa K.
    J Pharmacol Exp Ther; 1987 Jul 21; 242(1):263-8. PubMed ID: 3612533
    [Abstract] [Full Text] [Related]

  • 33. The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis.
    Albert DH, Malo PE, Tapang P, Shaughnessy TK, Morgan DW, Wegner CD, Curtin ML, Sheppard GS, Xu L, Davidsen SK, Summers JB, Carter GW.
    J Pharmacol Exp Ther; 1998 Jan 21; 284(1):83-8. PubMed ID: 9435164
    [Abstract] [Full Text] [Related]

  • 34. Comparison of the reversed passive Arthus and local Shwartzman reactions of rabbit skin: effects of the long-acting PAF antagonist UK-74,505.
    Norman KE, Williams TJ, Rossi AG.
    Br J Pharmacol; 1997 Apr 21; 120(7):1286-93. PubMed ID: 9105704
    [Abstract] [Full Text] [Related]

  • 35. Evidence for a direct effect on vascular permeability of platelet-activating factor induced hemoconcentration in the guinea pig.
    Handley DA, Lee ML, Saunders RN.
    Thromb Haemost; 1985 Dec 17; 54(4):756-9. PubMed ID: 4089809
    [Abstract] [Full Text] [Related]

  • 36. Effects of a novel PAF antagonist, E6123, on PAF-induced biological responses.
    Tsunoda H, Sakuma Y, Harada K, Muramoto K, Katayama S, Horie T, Shimomura N, Clark R, Miyazawa S, Okano K.
    Agents Actions Suppl; 1990 Dec 17; 31():251-4. PubMed ID: 2080757
    [Abstract] [Full Text] [Related]

  • 37. Evidence that platelet activating factor may mediate some acute inflammatory responses. Studies with the platelet-activating factor antagonist, CV3988.
    Issekutz AC, Szpejda M.
    Lab Invest; 1986 Mar 17; 54(3):275-81. PubMed ID: 3951199
    [Abstract] [Full Text] [Related]

  • 38. Platelet activating factor (PAF) and tumor necrosis factor-alpha (TNF alpha) interactions in endotoxemic shock: studies with BN 50739, a novel PAF antagonist.
    Rabinovici R, Yue TL, Farhat M, Smith EF, Esser KM, Slivjak M, Feuerstein G.
    J Pharmacol Exp Ther; 1990 Oct 17; 255(1):256-63. PubMed ID: 2213560
    [Abstract] [Full Text] [Related]

  • 39. In vitro and in vivo pharmacological profiles of the PAF receptor antagonist SRI 63-675.
    Handley DA, Van Valen RG, Winslow CM, Tomesch JC, Saunders RN.
    Thromb Haemost; 1987 Apr 07; 57(2):187-90. PubMed ID: 3037718
    [Abstract] [Full Text] [Related]

  • 40. 2-(3-Pyridyl)thiazolidine-4-carboxamides. 1. Novel orally active antagonists of platelet-activating factor (PAF).
    Nagaoka H, Hara H, Suzuki T, Takahashi T, Takeuchi M, Matsuhisa A, Saito M, Yamada T, Tomioka K, Mase T.
    Chem Pharm Bull (Tokyo); 1997 Oct 07; 45(10):1659-64. PubMed ID: 9353894
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.